Institut Pasteur Korea - Screening Discovery Platform



Home >Research Discovery>Translation Research

Screening Discovery Platform

Introduction of group leader

David Shum, MS
Master Degree: New York University, USA (2002)
Senior Research Technician, Memorial Sloan Kettering Cancer Center, USA (2002-2004)
Assay Dev. Specialist, Memorial Sloan Kettering Cancer Center, USA (2004-2015)
Head, Assay Development & Screening, Institut Pasteur Korea (2015-present)

Office phone: +82-31-8018-8220
Office location: R5.29-1

Research Interests

The Screening Discovery Platform (SDP) group provides expertise in the early stages of the drug discovery pipeline for assay development and high-throughput screening. Our research activities enable discovery of small molecules and target identification for drug development, biomarkers, and elucidation of disease mechanisms. SDP works in close collaboration with each investigator, within Institut Pasteur Korea (IPK) and outside collaborators, providing guidance through all stages of the chemical and RNAi screening process:
 
• Assay development
• Assay validation
• Assay automation
• High-content or high-throughput screening
• Data analysis
 
SDP optimizes and validates all screening assays for IPK discovery biology programs such as bacterial (streptococcus pneumoniae, mycobacterium tuberculosis), parasitic (visceral leishmaniasis), and viral research (hepatitis B, EBOLA, MERS-CoV). In 2016, SDP was recognized by Drugs for Neglected Disease initiative (DNDi-IPK) for our role in a multi-collaborative effort to identify small molecules for therapies against visceral leishmaniasis and Chagas disease.
 
Our capabilities/assets include:

Pathogen and biological research conducted in fully-automated robotic platforms located in BSL-2+ and BSL-3 laboratories
Validating and formatting assays to 96/384/1536 well format to perform screening activities
Conducting screening assays covering a wide range of detection readouts including fluorescence, bioluminescence, absorbance, and imaging (confocal and epi-fluorescent)
Small chemical library collection of compounds identified as potential starting points for the development of novel therapeutics. Library is comprised of ~400,000 molecules covering diverse sources including synthetic, natural products, extracts, and FDA approved drugs to early drug discovery programs
Genomic platforms (siRNA and shRNA technology) to identify new targets and signaling pathways as well as uncover mechanism of actions
 

Recent Publications

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. 
Ji Yeun Kim, Seongman Bae, Soonju Park, Ji-Soo Kwon, So Yun Lim, Ji Young Park, Hye Hee Cha, Mi Hyun Seo, Hyun Jung Lee, Nakyung Lee, Jinyeong Heo, David Shum, Youngmee Jee, Sung-Han Kim
Immune Netw. 2021 Aug;21(4):e29

Collaborative virtual screening to elaborate an imidazo[1,2- a]pyridine hit series for visceral leishmaniasis. 
Yuichiro Akao, Stacie Canan, Yafeng Cao, Kevin Condroski, Ola Engkvist, Sachiko Itono, Rina Kaki, Chiaki Kimura, Thierry Kogej, Kazuya Nagaoka, Akira Naito, Hiromi Nakai, Garry Pairaudeau, Constantin Radu, Ieuan Roberts, Mitsuyuki Shimada, David Shum, Nao-Aki Watanabe, Huanxu Xie, Shuji Yonezawa, Osamu Yoshida, Ryu Yoshida, Charles Mowbray, Benjamin Perry
RSC Med Chem. 2021 Jan 21;12(3):384-393

Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs. 
Yongsuk Ku,  Joo-Hwan Park, Ryeongeun Cho, Yongki Lee, Hyoung-Min Park, MinA Kim, Kyunghoon Hur, Soo Young Byun,  Jun Liu, Young-suk Lee, David Shum, Dong-Yeop Shin, Youngil Koh, Je-Yoel Cho, Sung-Soo Yoon,  Junshik Hong, Yoosik Kim
Proc Natl Acad Sci USA. 2021 Mar 30;118(13):e2016289118

Identification of inhibitors of Bcl-2 family protein-protein interaction by combining the BRET screening platform with virtual screening. 
I-Seul Park, Haeng Ran Seo, Kideok Kim, Honggun Lee, David Shum, Inhee Choi, Jiho Kim
Biochem Biophys Res Commun. 2020 Jun 30;527(3):709-715

Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases. 
Nathalie Aulner, Anne Danckaert, JongEun Ihm, David Shum, Spencer L Shorte
Trends Parasitol. 2019 Jul;35(7):559-570